LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 42 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Mr. Evert Schimmelpennink is the President of LENZ Therapeutics Inc, joining the firm since 2024.
What is the price performance of LENZ stock?
The current price of LENZ is $8.5, it has increased 1.19% in the last trading day.
What are the primary business themes or industries for LENZ Therapeutics Inc?
LENZ Therapeutics Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is LENZ Therapeutics Inc market cap?
LENZ Therapeutics Inc's current market cap is $265.9M
Is LENZ Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for LENZ Therapeutics Inc, including 6 strong buy, 7 buy, 1 hold, 0 sell, and 6 strong sell